Kiniksa files Form 144 for 2,367 Class A shares

Kiniksa Pharmaceuticals (KNSA) submitted a Form 144 notice relating to the proposed sale of 2,367 Class A ordinary shares, reported in connection with a restricted stock lapse dated 04/01/2026.

Accepted by SEC EDGAR 04/06/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) submitted a Form 144 notice relating to the proposed sale of 2,367 Class A ordinary shares, reported in connection with a restricted stock lapse dated 04/01/2026. The filing lists Charles Schwab & Co., Inc. as the broker and references NASDAQ. A numeric line shows 45,900,637, which appears alongside other securities data in the excerpt.

Insights

Insider Transactions Analyst

Routine equity-compensation disposition notice tied to vested shares.

The filing shows a proposed sale under Form 144 for 2,367 Class A ordinary shares resulting from a restricted stock lapse dated 04/01/2026. Form 144 is a notice of intent to sell by an affiliate; it does not confirm execution or pricing.

Cash-flow treatment and proceeds recipients are not specified in the excerpt. Subsequent trading or Form 4/Form 5 filings would confirm actual sale details.

Key Figures

Shares proposed for sale: 2,367 shares Broker reference: Charles Schwab & Co. Document reference date: 04/06/2026 +2 more

5 metrics

Shares proposed for sale 2,367 shares Restricted stock lapse dated 04/01/2026

Broker reference Charles Schwab & Co. Broker listed on Form 144 notice

Document reference date 04/06/2026 Date shown adjacent to securities data

Listed numeric line 45,900,637 Numeric entry appearing in the excerpt alongside securities information

Monetary numeric line 114,989.00 Numeric entry present in the excerpt (unit not specified in excerpt)

Key Terms

Form 144, Restricted Stock Lapse, Equity Compensation

3 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Lapse financial

"Class A ordinary shares | 04/01/2026 | Restricted Stock Lapse"

Equity Compensation financial

"04/01/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 disclose about the transaction?

It discloses a proposed sale of 2,367 Class A ordinary shares tied to a restricted stock lapse dated 04/01/2026. The filing lists Charles Schwab & Co., Inc. as the broker and references NASDAQ.

Does the Form 144 confirm the shares were sold for KNSA?

No, Form 144 indicates an intent to sell rather than a completed trade. The excerpt shows a proposed sale notice; execution and pricing are not provided in the excerpt.

Who is the broker handling the proposed sale in the KNSA excerpt?

The broker is listed as Charles Schwab & Co., Inc. at the address shown in the excerpt. The filing connects that broker to the proposed sale of the shares.

Why is the term 'restricted stock lapse' mentioned in the KNSA filing?

Because the shares reported (2,367) arose from a restricted stock lapse dated 04/01/2026, indicating equity compensation vesting triggered the proposed resale notice.

What is the significance of the number 45,900,637 in the excerpt?

The excerpt lists 45,900,637 alongside securities data; the filing text does not label this number explicitly in the provided excerpt, so its precise meaning is not stated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001857177
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Moat Ross
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	2367	114989.00	45900637	04/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	04/01/2026	Restricted Stock Lapse	Kiniksa Pharmaceuticals, Ltd.			2367	04/01/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	04/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/13/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ross Moat
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)